Current progress of CDC20 in cancer development and targeting CDC20 for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Cell division cycle 20 homologue (CDC20) is a key component of the anaphase-promoting complex/cyclosome (APC/C).
• The APC/C-CDC20 complex regulates mitotic progression through targeted protein degradation.
• CDC20 overexpression is linked to various cancers, promoting tumor initiation, progression, and drug resistance.

Purpose of the Study:

• To review the biological functions of CDC20 in cancer.
• To discuss the role and mechanisms of CDC20 in solid tumors and hematological malignancies.
• To elucidate CDC20-targeted inhibitors, their clinical benefits, and challenges.

Main Methods:

• Literature review of CDC20's role in cancer.
• Analysis of CDC20's mechanisms in tumorigenesis and drug resistance.
• Summary of current CDC20 inhibitors and clinical data.

Main Results:

• CDC20 acts as an oncogenic factor across diverse malignancies.
• Dysregulated CDC20 is associated with poor clinical outcomes.
• Several CDC20 inhibitors are under investigation with varying clinical benefits.

Conclusions:

• CDC20 is a significant oncogenic driver and a potential therapeutic target.
• Targeting CDC20 is a promising strategy for anti-cancer therapies.
• Development of specific, safe, and potent CDC20 inhibitors is crucial for clinical application.